Loading...

Operating Model Reforms And Biomaterial Focus Will Unlock Efficiency

Published
16 Dec 24
Updated
04 Sep 25
AnalystConsensusTarget's Fair Value
€29.31
3.5% overvalued intrinsic discount
04 Sep
€30.34
Loading
1Y
19.5%
7D
-0.7%

Author's Valuation

€29.3

3.5% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Sep 25

As neither the net profit margin nor the discount rate have materially changed, fundamental valuation drivers remain stable and, as a result, the consensus analyst price target for Valmet Oyj is unchanged at €29.31. What's in the News Valmet will deliver a complete IntelliTissue 1600 tissue machine and related systems to PT Suparma Tbk's Surabaya mill, adding 26,500 annual tons of production capacity, with start-up planned for 2026.

Shared on01 May 25
Fair value Increased 4.96%

Shared on23 Apr 25
Fair value Decreased 4.64%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.74%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 5.15%

AnalystConsensusTarget has increased revenue growth from 3.4% to 4.1%.